Clinica E Investigacion En Arteriosclerosis · Oct 29, 2026
Clinical characterization of LDL-c/ApoB discordance in the metabolic patient: The "false control" as an independent marker of subclinical atherosclerosis
By Urbaneja Zumaquero V, Coca Prieto I, Rioja Villodres J et al.
INTRODUCTION AND OBJECTIVES: Low-density lipoprotein cholesterol (LDL-c) is the cornerstone of lipid-lowering therapy, but it may underestimate the true atherogenic burden in patients with cardiometabolic risk. The discordance between LDL-c (mass) and apolipoprotein B (ApoB, particle number) creates a state of hidden residual risk. The objective of this study was to evaluate the prevalence of this discordance and determine its clinical association with subclinical atherosclerosis. MATERIAL AND METHODS: A cross-sectional observational study was conducted in 103 high-risk patients (mean age 60 years; 62% men) treated in Internal Medicine consultations. Anthropometric parameters, glycemic, and lipid profiles were analyzed. Discordance was determined using the percentile method, and the "false control" status was defined based on the achievement of therapeutic targets according to clinical guidelines. Cardiovascular risk in patients without a previous cardiovascular event was estimated using the SCORE2/SCORE2-OP model. Subclinical atherosclerosis was defined as the presence of carotid plaque assessed by ultrasound. Spearman correlation tests, Kruskal-Wallis comparisons, and a multivariate logistic regression model adjusted for age, sex, and HbA1c were used. RESULTS: A sample with a high metabolic burden (80% hypertensive, 52% diabetic, BMI 31.9±5.4kg/m²) was included. A total lack of correlation was observed between LDL-c and ApoB (rho=-0.021; p=0.833). Twenty-nine percent presented high-ApoB discordance (subjects whose ApoB percentile exceeded that of LDL-c by>10 units), and 25% were in a state of "false control" (LDL-c on target with elevated ApoB). Patients with high-ApoB discordance showed a more adverse metabolic profile (HbA1c 6.3 vs. 5.8%; p=0.014). Plaque prevalence was significantly higher in the "false control" group (73.1%) than in the "true control" group (36.4%; p=0.035). Concordant lipid control was independently associated with the absence of plaque (OR 6.32; 95% CI: 1.43-27.87; p=0.015). CONCLUSIONS: LDL-c/ApoB discordance is highly prevalent in high-risk patients. In this context, the clinical situation of "false control" is independently associated with a higher burden of subclinical atherosclerosis. The systematic measurement of ApoB is essential to identify this hidden residual risk and optimize cardiovascular prevention in patients with a complex metabolic profile.
doi.org/10.1016/j.arteri.2026.500980PubMed 42957510Biomarkers